Neuer Markt Drives German Shopping Spree
Capitalizing on their hefty valuations, German public biotechs are going on a shopping spree, swapping stock for other companies and thereby creating broader platforms of technologies and in some cases clinical pipelines. In their zest for turning their paper into harder industrial assets, German biotechs are showing themselves far more aggressive than the majority of their American and British counterparts.
You may also be interested in...
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.